LGND Stock Analysis: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$319.55
7.54 (2.42%)
▲
5d:
+7.99%
30d:
+37.29%
90d:
+60.08%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: LGND is 9.5% above its trading range ($291.88). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: LGND is 9.5% above its trading range ($291.88). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$482.11
Based on 14.2% avg growth
INTRINSIC VALUE TODAY
$299.35
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $319.55, which is considered extended relative to its 30-day fair value range of $232.66 to $291.88. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.2) compared to its historical average (22.2). At these levels, the market is pricing in 8.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is approaching resistance at $320.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LGND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $277.60. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is approaching resistance at $320.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LGND has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $277.60. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$232.66 -
$291.88
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.7%
Protect Your Profits
LGND is technically overbought (RSI 80). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+9.5% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 13.1% above Wall St target ($277.60)
- NEUTRAL: PE elevated vs history but 8.4% growth expectation is conservative given 103% recent growth
Trading Range Analysis
30-Day Trading Range
$232.66 -
$291.88
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$17.15
(5.4%)
Support & Resistance Levels
Support Level
$245.00
Resistance Level
$320.99
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.24
Wall Street Target
$277.60
(-13.1%)
Revenue Growth (YoY)
14.1%
Earnings Growth (YoY)
103.2%
Profit Margin
56.0%
Valuation Premium vs History
+8.4% premium
PE vs Historical
28.2 vs 22.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.4%
(market-implied from PE analysis)
1-Year Target
$346.39
(+8%)
2-Year Target
$375.49
(+18%)
3-Year Target
$407.03
(+27%)
3-Yr Target (if PE normalizes)
(PE: 28→22)
PE COMPRESSION
$320.01
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.2, Growth: 24.3%)
$614.29
(+92%)
Base:
(SPY PE: 21.8, Growth: 24.3%)
$473.82
(+48%)
Bear:
(PE: 18.5, Growth: 24.3%)
$402.75
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (41x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Trailing PE: 40.68 | Current EPS (TTM): $7.67
Bull Case
$506.39
(+59%)
Analyst growth 47.5%, PE expands to 44.8
Base Case
$460.36
(+44%)
Market implied 47.5%, PE stable at 40.7
Bear Case
$212.17
(-34%)
Severe decline -20.0%, PE contracts to 34.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 04, 2026 10:10 AM ET
Data refreshes hourly during market hours. Next update: 11:10 AM
Data refreshes hourly during market hours. Next update: 11:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
2
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
John W Kozarich
SELL
467 shares
2026-04-01
Andrew Reardon
SELL
5000 shares
2026-04-01
Stephen L Sabba
SELL
1000 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
